07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Multiplicom sales and marketing update

Multiplicom launched genomic and somatic mutation detection kits based on its MASTR technology for investigational use. Separate MASTR kits were launched to detect genomic mutations for diseases including mucovisidosis, Marfan syndrome, Alport syndrome, polycystic kidney...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Clinical News

BRCA MASTR Dx test regulatory update

Multiplicom said it received CE Mark approval for its BRCA MASTR Dx test to identify mutations in the coding regions of the breast cancer 1 early onset (BRCA1) and BRCA2 genes in subjects...